1. Home
  2. CIVB vs ANL Comparison

CIVB vs ANL Comparison

Compare CIVB & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Civista Bancshares Inc.

CIVB

Civista Bancshares Inc.

N/A

Current Price

$27.40

Market Cap

571.6M

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

N/A

Current Price

$13.86

Market Cap

611.1M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CIVB
ANL
Founded
1884
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
571.6M
611.1M
IPO Year
2012
2022

Fundamental Metrics

Financial Performance
Metric
CIVB
ANL
Price
$27.40
$13.86
Analyst Decision
Buy
Strong Buy
Analyst Count
5
1
Target Price
$26.60
$20.00
AVG Volume (30 Days)
143.7K
139.0K
Earning Date
04-22-2026
04-10-2026
Dividend Yield
2.90%
N/A
EPS Growth
31.34
N/A
EPS
1.41
N/A
Revenue
$19,023,000.00
N/A
Revenue This Year
$14.88
$36.02
Revenue Next Year
$5.99
N/A
P/E Ratio
$19.44
N/A
Revenue Growth
N/A
N/A
52 Week Low
$19.84
$0.88
52 Week High
$29.97
$17.25

Technical Indicators

Market Signals
Indicator
CIVB
ANL
Relative Strength Index (RSI) 45.65 54.40
Support Level $27.00 $12.45
Resistance Level $29.31 $15.29
Average True Range (ATR) 0.53 0.96
MACD -0.05 -0.09
Stochastic Oscillator 50.00 45.32

Price Performance

Historical Comparison
CIVB
ANL

About CIVB Civista Bancshares Inc.

Civista Bancshares Inc is a financial holding company. Operating through its subsidiary, it engages in the business of community banking. Its business activity involves collecting customer deposits, making loans, purchasing securities, and offering trust services to its clients. The company's loan portfolio includes commercial and agricultural, commercial real estate-owner occupied, commercial real estate non-owner occupied, residential real estate, real estate construction, and consumer loans. The majority of its revenues are derived from the interest and fees gained on loans.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: